Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial.
作者： Ching‐Lung Lai , Anna Suk‐Fong Lok , Pui‐Chee Wu , Gerald Chee‐Bunn Chan , Hsiang‐Ju Lin
DOI: 10.1002/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L
关键词: Doxorubicin 、 Cardiotoxicity 、 Internal medicine 、 Antitumor therapy 、 Gastroenterology 、 Oncology 、 Hepatocellular carcinoma 、 Randomized controlled trial 、 Medicine 、 Tumor regression 、 Neutropenia 、 Median survival
摘要: To assess the efficacy and safety of Adriamycin (Adria Laboratories, Columbus, OH) in inoperable hepatocellular carcinoma (HCC), 60 patients were randomized to receive 75 mg/m2 at 3-week intervals 46 no antitumor therapy. The median survival rate group was 10.6 weeks; that receiving therapy 7.5 weeks (P = 0.036). induced tumor regression 25% 50% 5% over only 3.3% patients. It caused fatal complications (septicemia cardiotoxicity) severity neutropenia leading septicemia for a particular dose unpredictable. Four eight who developed cardiotoxicity received less than 500 Adriamycin. We conclude is not an ideal drug treatment HCC.
hku.hk
sci-hub.se 参考文章(16)
Tat Kuen Choi, Nim Wang Lee, John Wong, Chemotherapy for advanced hepatocellular carcinoma Adriamycin versus quadruple chemotherapy Cancer. ,vol. 53, pp. 401- 405 ,(1984) , 10.1002/1097-0142(19840201)53:3<401::AID-CNCR2820530306>3.0.CO;2-L
Charles L. M. Olweny, Tom Toya, Edward Katongole-Mbidde, Josua Mugerwa, Sebastian K. Kyalwazi, Herman Cohen, Treatment of hepatocellular carcinoma with adriamycin.Preliminary communication Cancer. ,vol. 36, pp. 1250- 1257 ,(1975) , 10.1002/1097-0142(197510)36:4<1250::AID-CNCR2820360410>3.0.CO;2-X
Elio Sciarrino, Rosa Giovanna Simonetti, Salvatore Le Moli, Luigi Pagliaro, Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer. ,vol. 56, pp. 2751- 2755 ,(1985) , 10.1002/1097-0142(19851215)56:12<2751::AID-CNCR2820561205>3.0.CO;2-O
R.H.J. Houwen, C.M.A. Bijleveld, H.G. de Vries-Hospers, Ciprofloxacin for cholangitis after hepatic portoenterostomy. The Lancet. ,vol. 1, pp. 1367- 1367 ,(1987) , 10.1016/S0140-6736(87)90663-5
G.E Burch, Of generic medicine bottles. American Heart Journal. ,vol. 99, pp. 671- 671 ,(1980) , 10.1016/0002-8703(80)90742-5
FRANK M. TORTI, Reduced Cardiotoxicity of Doxorubicin Delivered on a Weekly Schedule Annals of Internal Medicine. ,vol. 99, pp. 745- 749 ,(1983) , 10.7326/0003-4819-99-6-745
Charles L. M. Olweny, Edward Katongole-Mbidde, Silver Bahendeka, David Otim, Jusua Mugerwa, Sebastian K. Kyalwazi, Further experience in treating patients with hepatocellular carcinoma in Uganda Cancer. ,vol. 46, pp. 2717- 2722 ,(1980) , 10.1002/1097-0142(19801215)46:12<2717::AID-CNCR2820461230>3.0.CO;2-T
J. Vilaseca, J. Guardia, R. Bacardí, J. Monné, DOXORUBICIN FOR LIVER CANCER The Lancet. ,vol. 311, pp. 1367- ,(1978) , 10.1016/S0140-6736(78)92448-0
C. L. Lai, K. C. Lam, K. P. Wong, P. C. Wu, D. Todd, Clinical features of hepatocellular carcinoma: Review of 211 patients in Hong Kong Cancer. ,vol. 47, pp. 2746- 2755 ,(1981) , 10.1002/1097-0142(19810601)47:11<2746::AID-CNCR2820471134>3.0.CO;2-K
James H. McKillop, Michael R. Bristow, Michael L. Goris, Margaret E. Billingham, Kaylyn Bockemuehl, Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. American Heart Journal. ,vol. 106, pp. 1048- 1056 ,(1983) , 10.1016/0002-8703(83)90651-8